<SEC-DOCUMENT>0001601485-25-000090.txt : 20250520
<SEC-HEADER>0001601485-25-000090.hdr.sgml : 20250520
<ACCEPTANCE-DATETIME>20250520160800
ACCESSION NUMBER:		0001601485-25-000090
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250519
FILED AS OF DATE:		20250520
DATE AS OF CHANGE:		20250520

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Ashe Carol Gail
		CENTRAL INDEX KEY:			0001761748
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39990
		FILM NUMBER:		25968792

	MAIL ADDRESS:	
		STREET 1:		C/O APTOSE BIOSCIENCES INC.
		STREET 2:		251 CONSUMERS ROAD, SUITE 1105
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M2J 4R3

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Elicio Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001601485
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				113430072
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210
		BUSINESS PHONE:		(857) 209-0050

	MAIL ADDRESS:	
		STREET 1:		451 D STREET, 5TH FLOOR
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02210

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Angion Biomedica Corp.
		DATE OF NAME CHANGE:	20140228
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>wk-form4_1747771672.xml
<DESCRIPTION>FORM 4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-05-19</periodOfReport>

    <notSubjectToSection16>0</notSubjectToSection16>

    <issuer>
        <issuerCik>0001601485</issuerCik>
        <issuerName>Elicio Therapeutics, Inc.</issuerName>
        <issuerTradingSymbol>ELTX</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001761748</rptOwnerCik>
            <rptOwnerName>Ashe Carol Gail</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ELICIO THERAPEUTICS, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>451 D STREET, 5TH FLOOR, SUITE 501</rptOwnerStreet2>
            <rptOwnerCity>BOSTON</rptOwnerCity>
            <rptOwnerState>MA</rptOwnerState>
            <rptOwnerZipCode>02210</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable></nonDerivativeTable>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (Right to Buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>5.84</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-05-19</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>7900</value>
                    <footnoteId id="F1"/>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-05-19</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>7900</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>7900</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The stock option shall vest and become exercisable in full on the earlier of (A) May 19, 2026, the one-year anniversary of the date of grant and (B) the next annual meeting of the Company's stockholders after
the grant date, subject to the Reporting Person continuing to provide services to the Issuer through such vesting date.</footnote>
    </footnotes>

    <remarks></remarks>

    <ownerSignature>
        <signatureName>/s/ Carol Ashe</signatureName>
        <signatureDate>2025-05-20</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
